-
公开(公告)号:US09273057B2
公开(公告)日:2016-03-01
申请号:US14414152
申请日:2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor: Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07D487/08 , C07D487/10 , C07D471/10 , C07D498/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61P19/02 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07F9/6521 , C07D519/00 , C07F9/6561 , C07F7/18
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
12.
公开(公告)号:US20150065465A1
公开(公告)日:2015-03-05
申请号:US14532218
申请日:2014-11-04
Applicant: Bristol-Myers Squibb Company
Inventor: Ashok Vinayak Purandare , Brian E. Fink , Ashvinikumar V. Gavai , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann
IPC: C07D487/04 , A61K45/06 , A61K31/541 , C07D487/08 , A61K31/5383 , C07D519/00 , A61K31/55 , A61K31/5377 , C07F9/6561 , A61K31/675 , A61K31/53 , A61K31/551
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)咪唑三嗪抑制蛋白激酶活性,从而使它们用作抗癌剂。
-